标题:Research Progress on Artemisinin and Its Derivatives against Hematological Malignancies
作者:Li Y.; Shan N.-N.; Sui X.-H.
作者机构:[Li, Y] Department of Hematology, Shandong Provincial Hospital Affiliated to Shandong University, Jinan, 250021, China;[ Shan, N.-N] Department of Hem 更多
通讯作者:Li, Y(yingren10301@sina.com)
通讯作者地址:[Li, Y] Department of Hematology, Shandong Provincial Hospital Affiliated to Shandong UniversityChina;
来源:Chinese Journal of Integrative Medicine
出版年:2020
DOI:10.1007/s11655-019-3207-3
关键词:artemisinin; artesunate; dihydroartemisinin; hematological malignancies; review
摘要:Although current therapeutic methods against hematological malignancies are effective in the early stage, they usually lose their effectiveness because of the development of drug resistances. Seeking new drugs with significant therapeutic effects is one of the current research hotspots. Artemisinin, an extract from the plant Artemisia annua Linne, and its derivatives have excellent antimalarial effects in clinical applications as well as excellent safety. Recent studies have documented that artemisinin and its derivatives (ARTs) also have significant effects against multiple types of tumours, including hematological malignancies. This review focuses on the latest research achievements of ARTs in the treatment of hematological malignancies as well as its mechanisms and future applications. The mechanisms of ARTs against different types of hematological malignancies mainly include cell cycle arrest, induction autophagy and apoptosis, inhibition of angiogenesis, production of reactive oxygen species, and induction of differentiation. Additionally, the review also summarizes the anticancer effects of ARTs in many drug-resistant hematological malignancies and its synergistic effects with other drugs. © 2019, The Chinese Journal of Integrated Traditional and Western Medicine Press and Springer-Verlag GmbH Germany, part of Springer Nature.
收录类别:SCOPUS
资源类型:期刊论文
原文链接:https://www.scopus.com/inward/record.uri?eid=2-s2.0-85079468868&doi=10.1007%2fs11655-019-3207-3&partnerID=40&md5=225a070f9ead5ee1c8484ff0aea21624
TOP